[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial in treating cancers with EGFR-sensitive mutations.
• Clinical and basic research is increasingly focusing on the therapeutic potential of EGFR-TKIs.

Purpose of the Study:

• To review the latest research developments concerning EGFR-targeted drugs.
• To provide an overview of advancements in EGFR-TKI research up to 2016.

Main Methods:

• Literature review of scientific publications.
• Analysis of clinical and basic research findings on EGFR-TKIs.

Main Results:

• EGFR-TKIs have demonstrated substantial clinical benefits for patients with specific EGFR mutations.
• The field of EGFR-targeted therapy has seen significant research attention and development.

Conclusions:

• EGFR-TKIs represent a key therapeutic strategy for EGFR-mutated cancers.
• Continued research is essential for advancing EGFR-targeted drug development and application.